p53 gene determines radiation efficacy:
This article was originally published in Clinica
The status of an individual's p53 gene product may have a bearing on how effective radiation is for treating some prostate cancer patients, say US researchers. Under normal conditions, the natural tumour-killing effects of the p53 gene product can be activated or enhanced by radiation therapy. An abnormal or mutated gene, however, renders it unable to suppress tumours or facilitate the killing of tumour cells by radiation, researchers from the University of Winconsin Comprehensive Cancer Center, report in the International Journal of Radiation Oncology, Biology and Physics (July).
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.